Evidence map›Paper›PMID 25897373›Full record

ArticleFacts, views & vision in ObGyn2015

Immunological parameters as a new lead in the diagnosis of ovarian cancer.

T Baert, D Timmerman, I Vergote, A Coosemans

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Facts, views & vision in ObGyn, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

T BaertUZ Leuven, Gynaecology and Obstetrics, Herestraat 49, 3000 Leuven, Belgium. ; Department of Oncology, Leuven Cancer Institute, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
D TimmermanUZ Leuven, Gynaecology and Obstetrics, Herestraat 49, 3000 Leuven, Belgium. ; Department of Development and Regeneration, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
I VergoteUZ Leuven, Gynaecology and Obstetrics, Herestraat 49, 3000 Leuven, Belgium. ; Department of Oncology, Leuven Cancer Institute, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
A CoosemansUZ Leuven, Gynaecology and Obstetrics, Herestraat 49, 3000 Leuven, Belgium. ; Department of Oncology, Leuven Cancer Institute, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is the leading cause of pelvic gynecological cancer death in Europe. Prognosis is poor in women diagnosed at stage III to IV or in case disease recurs. Platin-based chemotherapy and radical surgery have already improved prognosis significantly. Novel strategies in the treatment of ovarian cancer are being searched for. The study of the immune system as a valuable parameter in the development of ovarian cancer has been neglected for a long time. Nevertheless, this is a field in full progression and might open new perspectives in the diagnosis and prognosis of ovarian cancer patients and could lead to a more motivated choice of targeted therapies.

Indexed as

diagnosisimmunosuppressionmyeloid derived suppressor cellsOvarian cancerprognostic markerregulatory T celltumor-associated macrophages

Identifiers

PMID25897373
PMCPMC4402445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.